title: The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants.
abstract: Deep venous thromboses can be divided into two groups according to their pathogenesis, anatomical features and differing responses to therapy. The first and most frequent consists of so-called simple venous thrombosis while the second group, which is less common, comprises severe or recurrent venous thrombosis characterised by a multifactorial pathogenesis, a mixed thrombus rich in platelets and by an incomplete response to both prophylactic and therapeutic treatment with anticoagulants (heparin or vitamin K antagonist). In a randomized, prospective blind study in patients with severe or recurrent venous thrombosis, which included 6 groups each of 100 patients, co-administration of anticoagulants with various types of antiplatelet agent, either with rheological effects (piracetam, buflomedil, pentoxifylline) or without them (dipyridamole), has shown a beneficial potentiating antithrombotic effect with those drugs possessing rheological effects and the absence of this effect with dipyridamole.
authors.affiliation: Department of Internal Medicine, Haematology Division, Haemostasis and Thrombosis Unit, University of Louvain (UCL), St.-Luc University Clinics, Brussels, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Moriau
authors.forename: E
authors.initials: E
authors.lastname: Lavenne-Pardonge
authors.forename: L
authors.initials: L
authors.lastname: Crasborn
authors.forename: R
authors.initials: R
authors.lastname: von Frenckell
authors.forename: C
authors.initials: C
authors.lastname: Col-Debeys
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests; D001809:Blood Viscosity / Q000187:drug effects; D004176:Dipyridamole / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D018056:Hemorheology / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage; D010889:Piracetam / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000008:administration & dosage; D012008:Recurrence; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D011759:Pyrrolidines; D014812:Vitamin K; D004176:Dipyridamole; D006493:Heparin; D010431:Pentoxifylline; C010651:buflomedil; D010889:Piracetam